Efficacy of acarbose and metformin in newly diagnosed type 2 diabetes patients stratified by HbA1c levels

Journal of Diabetes
Jinping ZhangWenying Yang

Abstract

The aim of the present study was to investigate whether the therapeutic efficacy of acarbose and metformin is correlated with baseline HbA1c levels in Chinese patients with newly diagnosed type 2 diabetes mellitus (T2DM). Data for 711 subjects were retrieved from the MARCH (Metformin and AcaRbose in Chinese as initial Hypoglycemic treatment) trial database and reviewed retrospectively. Patients were grouped according to baseline HbA1c levels (<7%, 7%-8%, and >8%) and the results for these three groups were compared between acarbose and metformin treatments. Acarbose and metformin treatment significantly improved T2DM-associated parameters (weight, fasting plasma glucose [FPG], postprandial glucose [PPG], glucagon-like peptide-1 [GLP-1], HOMA-IR, and total cholesterol) across all HbA1c levels. Acarbose decreased PPG and HOMA-β significantly more than metformin, but only in subjects with lower baseline HbA1c (PPG in the <7% and 7%-8%, HOMA-β in the <7% groups; all P < 0.05). Acarbose decreased triglyceride (TG) levels, and the areas under the curve (AUC) for insulin and glucagon more than metformin at all HbA1c levels (P < 0.05). After 24 weeks treatment, metformin decreased FPG levels significantly more than acarbose for all bas...Continue Reading

References

Jul 24, 2003·JAMA : the Journal of the American Medical Association·Jean-Louis ChiassonUNKNOWN STOP-NIDDM Trial Research Group
Jan 27, 2005·Drugs·Andrew J Krentz, Clifford J Bailey
Sep 12, 2008·The New England Journal of Medicine·Rury R HolmanH Andrew W Neil
Mar 26, 2010·The New England Journal of Medicine·Wenying YangUNKNOWN China National Diabetes and Metabolic Disorders Study Group
Mar 21, 2012·Diabetes Care·Rui LiWei Jian Zhong
Sep 5, 2013·JAMA : the Journal of the American Medical Association·Yu XuUNKNOWN 2010 China Noncommunicable Disease Surveillance Group
Sep 25, 2014·International Journal of Medical Sciences·Yanling WuWen Zhang

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Related Concepts

Related Feeds

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.

Cardiovascular Biology of GLP-1

Glucagon-like peptide 1 (GLP-1) plays a role in glucose metabolism, energy homeostasis, and inflammation suppression. GLP-1 receptor signaling has been shown to impact cardiovascular function. This feed focuses on the role of GLP-1 and GLP-1 receptor agonists on cardiovascular biology.